Pharmacology of Nitrous Oxide (N₂O)

Introduction and Basic Properties

Nitrous oxide ($N_2O$) is an inorganic inhalational agent that has been used in anaesthetic practice for over 150 years. It is a colourless, odourless gas at room temperature with a sweet taste. As an incomplete anaesthetic - meaning it cannot produce surgical anaesthesia on its own at atmospheric pressure - it is most commonly used as an adjuvant agent to reduce requirements for other volatile or intravenous anaesthetics, and for its significant analgesic properties.

Key Physicochemical Properties

Pharmacokinetics

Uptake and Distribution - The $F_A/F_I$ Relationship

The alveolar fraction ($F_A$) relative to the inspired fraction ($F_I$) is the key determinant of the speed of induction. The rate of rise of $F_A/F_I$ depends on:

1. Inspired concentration / delivered concentration
2. Alveolar ventilation
3. Blood solubility (blood:gas partition coefficient)
4. Cardiac output
5. Alveolar-to-venous partial pressure difference

Solubility and Rapid Onset

The blood:gas partition coefficient of $N_2O$ is 0.47, indicating it is relatively insoluble in blood. This means:

• At equilibrium, the concentration in blood is less than half that in the alveolar space
• Very few molecules dissolve in pulmonary blood before the partial pressure equilibrates
• The $F_A/F_I$ ratio rises rapidly towards 1.0 - equilibrium is achieved quickly
• This translates to rapid onset and rapid recovery

This contrasts with highly soluble agents such as halothane (blood:gas = 2.30), where many molecules dissolve in blood before the partial pressure rises significantly.

Effect of Ventilation

Because $N_2O$ has low blood solubility, alveolar partial pressure rises quickly without relying on ventilation to "replenish" the alveolar concentration. Increased ventilation therefore has a relatively minor effect on the speed of equilibration:

A fourfold increase in ventilation rate increases the $F_A/F_I$ ratio for nitrous oxide by only ~15%, whereas for halothane it almost doubles the ratio in the first few minutes.

This is the opposite of the situation with highly soluble agents, where hyperventilation substantially accelerates induction.

Effect of Cardiac Output

An increase in pulmonary blood flow (increased cardiac output) increases the uptake of anaesthetic gas from the alveolar space. For $N_2O$:

• Increased cardiac output increases alveolar uptake, which slows the rate at which $F_A/F_I$ rises
• This effect is clinically less pronounced for $N_2O$ than for more soluble agents, because there is limited capacity for blood to absorb the relatively insoluble $N_2O$ in the first place

The Concentration Effect

When $N_2O$ is administered in high concentrations, its rapid absorption from the alveoli into blood:

• Concentrates any co-administered volatile agent remaining in the alveolar space
• Raises the partial pressure of the volatile agent above what would otherwise be expected from the inspired mixture
• This accelerates the equilibration and induction speed of the co-administered volatile agent

This is termed the concentration effect.

The Second Gas Effect

When large volumes of $N_2O$ are absorbed rapidly into the pulmonary circulation:

• The volume of gas in the alveoli is reduced
• Inspired gas is drawn in to replace it - augmenting the delivery of any co-administered volatile agent to the alveoli
• This second gas effect further accelerates the uptake of the second volatile agent

Recovery

Recovery from $N_2O$ is rapid because of its low blood solubility: - Upon cessation of delivery, $N_2O$ rapidly moves from blood back into alveoli and is exhaled - The brain:blood partition coefficient of 1.1 means brain concentration closely tracks blood concentration - Recovery is therefore as rapid as induction

Diffusion Hypoxia

At the end of $N_2O$ anaesthesia, large volumes of $N_2O$ rapidly move from blood into the alveolar space. This can: - Dilute alveolar oxygen, reducing $P_AO_2$ - Cause transient hypoxia if supplemental oxygen is not administered - This is managed by administering 100% oxygen for several minutes at the end of anaesthesia (a period sometimes called "washout")

Metabolism

$N_2O$ undergoes no appreciable metabolism in the body. This is a key distinguishing feature compared to halogenated volatile agents such as halothane (>40% metabolised). There are no hepatotoxic metabolites. However, $N_2O$ does interact with vitamin B₁₂ through oxidation of its cobalt centre (this mechanism is noted for completeness, though the absence of metabolic breakdown of $N_2O$ itself).

Pharmacodynamics

Mechanism of Action

The precise molecular mechanism of volatile and gaseous anaesthetic agents remains an area of ongoing investigation. $N_2O$ is understood to act through:

• Antagonism of NMDA (N-methyl-D-aspartate) glutamate receptors - contributing to its anaesthetic and analgesic effects
• Enhancement of inhibitory neurotransmission (GABA-A receptor modulation) - though this contribution is less certain
• Consistent with the Meyer-Overton lipid solubility hypothesis, potency correlates with oil:gas partition coefficient; however, receptor-based mechanisms are now considered important

MAC and Anaesthetic Potency

$N_2O$ has a MAC of >100%, meaning that even at atmospheric pressure it cannot prevent movement in response to surgical stimulation in 50% of patients. It is therefore an incomplete anaesthetic:

The low potency of $N_2O$ is consistent with its low oil:gas (lipid) solubility relative to potent halogenated agents.

Analgesic Properties

$N_2O$ produces significant analgesia at sub-anaesthetic concentrations (e.g. 50% $N_2O$ in oxygen, as in Entonox®). This is mediated in part through:

• NMDA receptor antagonism
• Endogenous opioid pathway activation

This analgesic effect is clinically useful for procedural pain and labour analgesia.

Cardiovascular Effects

• $N_2O$ is a mild myocardial depressant in isolation; however, in clinical use it tends to stimulate the sympathetic nervous system, maintaining or slightly increasing heart rate and blood pressure
• It increases pulmonary vascular resistance - this is clinically significant in patients with pulmonary hypertension or right heart failure
• Overall haemodynamic effects are generally mild in healthy patients

Respiratory Effects

• Causes mild respiratory depression but much less than potent volatile agents
• Increases respiratory rate slightly while decreasing tidal volume
• Does not significantly suppress hypoxic pulmonary vasoconstriction

Central Nervous System Effects

• Produces sedation, anxiolysis, and analgesia at sub-anaesthetic concentrations
• Increases cerebral blood flow and cerebral metabolic rate slightly - important in neuroanaesthesia contexts
• Can cause euphoria - hence historical misuse

Special Pharmacological Considerations

Expansion of Gas-Containing Cavities

$N_2O$ is 34 times more soluble than nitrogen in blood. When it is administered, it enters gas-filled spaces far more rapidly than nitrogen leaves. This causes volume expansion in:

• Pneumothorax - can become life-threatening
• Bowel gas - expansion during abdominal surgery
• Middle ear - pressure increase behind the tympanic membrane
• Pneumocephalus - post-neurosurgery
• Vitreous gas bubbles - following ophthalmic surgery (e.g. SF₆ gas tamponade)
• Air emboli - entrainment expands the volume of vascular air

Vitamin B₁₂ and Methionine Synthase

$N_2O$ irreversibly oxidises the cobalt atom in vitamin B₁₂ (cobalamin), inactivating methionine synthase. Consequences include:

• Impaired DNA synthesis (megaloblastic changes)
• Impaired myelin synthesis (subacute combined degeneration of the spinal cord with prolonged exposure)
• Clinically relevant with prolonged or repeated exposure (e.g. ITU sedation, repeated anaesthetics, occupational exposure)
• Risk is heightened in patients with pre-existing B₁₂ deficiency or those taking methotrexate

Teratogenicity and Occupational Exposure

• Chronic occupational exposure to $N_2O$ has been associated with increased risk of spontaneous abortion and reproductive effects, related to methionine synthase inhibition
• Theatre scavenging systems are required to minimise staff exposure

Comparative Properties Table

Clinical Relevance

Role in Modern Anaesthesia

• Used as a carrier gas (typically 50-70% in oxygen) to reduce requirements for volatile agents - a MAC-sparing effect
• Provides analgesia as a component of balanced anaesthesia
• Entonox (50% $N_2O$ / 50% $O_2$) used for procedural pain, labour analgesia, and emergency analgesia

Practical Considerations for the Anaesthetist

1. Contraindications: $N_2O$ should be avoided where gas expansion in closed spaces would be hazardous:
2. Pneumothorax (or suspected)
3. Middle ear surgery
4. Retinal surgery with intraocular gas
5. Suspected air embolus
6. Bowel obstruction

7. Pneumocephalus

8. Diffusion hypoxia: Administer 100% oxygen for a minimum of several minutes at the end of $N_2O$ anaesthesia to prevent dilutional hypoxia

9. Concentration and second gas effects: Useful for speeding induction with volatile agents - taking advantage of $N_2O$'s rapid alveolar equilibration

10. PONV: $N_2O$ is an independent risk factor for postoperative nausea and vomiting; should be avoided or used cautiously in high-risk patients

11. Pulmonary hypertension: Avoided in patients with elevated pulmonary vascular resistance

12. Prolonged use and B₁₂: Avoid in patients with known B₁₂ deficiency, those on antifolates, and wherever prolonged exposure is anticipated (e.g. >6 hours, ITU sedation)

13. Neuroanaesthesia: Mild increase in cerebral blood flow and ICP - used cautiously in patients with raised ICP or poor intracranial compliance

14. Environmental impact: $N_2O$ is a significant greenhouse gas and contributes to ozone depletion; environmental sustainability is increasingly influencing decisions to use or reduce $N_2O$ in anaesthetic practice